Global Perspectives in the Treatment of EGFR-mutant Resectable and Advanced NSCLC

Expert oncologists from key Asian countries share guidelines for biomarker testing in their countries and how biomarker testing is being used for non–small cell lung cancer in their region.

Shared insight on how comprehensive biomarker testing should be in non–small cell lung cancer, as well as what may or may not be reimbursed.

A broad review on how biomarker testing has impacted the clinical staging and management of non–small cell lung cancer across geographic regions.

A comprehensive discussion on the value and limitations of tissue-based versus liquid-based biomarker testing in non–small cell lung cancer.

Perspectives on optimal treatment approaches for patients with resectable non–small cell lung cancer in Asia, with a focus on stage IB disease.

A brief discussion on the use of postoperative radiotherapy in non–small cell lung cancer following resection.

Shared insight on the clinical implications of the ADAURA trial, which tested osimertinib as adjuvant therapy following resection in patients with EGFR-positive NSCLC.

Experts consider if there’s a role for the continued use of first-generation TKIs in patients with resected EGFR-positive non–small cell lung cancer.

In light of evolving treatment options for resectable non–small cell lung cancer, panelists discuss biomarker testing to guide adjuvant therapy in the postoperative setting.

Closing out their discussion on resectable NSCLC, experts review multidisciplinary care strategies and the role of neoadjuvant therapy in patients identified for resection.

A comprehensive discussion on frontline treatment options for patients with EGFR+ advanced non–small cell lung cancer.

Experts review frontline combination approaches with bevacizumab in EGFR+ advanced non–small cell lung cancer.

Following treatment failure on frontline TKIs in EGFR+ advanced NSCLC, experts consider biomarker testing to inform second-line treatment.

Panelists consider optimal second-line therapy for patients who acquired resistance to frontline TKIs in EGFR+ advanced NSCLC.

Expert perspectives on the management of C797S-mutated non–small cell lung cancer following failure of frontline TKIs.

Global perspectives on the future management of EGFR+ non–small cell lung cancer given recent advances in the treatment paradigm.